Valuation: Lundbeck

Market Cap 41.26B 6.31B 5.52B 5.09B 4.69B 8.85B 608B 9.04B 60.86B 23.94B 298B 23.71B 23.19B 1,025B P/E 2026 *
9.39x
P/E 2027 * 9.34x
Enterprise Value 45.35B 6.94B 6.07B 5.6B 5.16B 9.72B 668B 9.94B 66.89B 26.31B 327B 26.06B 25.49B 1,127B EV / Sales 2026 *
1.76x
EV / Sales 2027 * 1.59x
Free-Float
30.76%
Yield 2026 *
3.5%
Yield 2027 * 3.58%
1 day+0.82%
1 week+1.10%
Current month+0.27%
1 month+2.66%
3 months+4.56%
6 months-7.44%
Current year+1.38%
1 week 35.75
Extreme 35.75
36.85
1 month 35.75
Extreme 35.75
37.75
Current year 31.4
Extreme 31.4
39.9
1 year 28.5
Extreme 28.5
39.9
3 years 23.3
Extreme 23.3
41.7
5 years 21.94
Extreme 21.935
41.7
10 years 21.94
Extreme 21.935
41.7
Manager TitleAgeSince
Chief Executive Officer 59 01/10/2023
Director of Finance/CFO 49 01/09/2022
Chief Operating Officer 52 -
Director TitleAgeSince
Director/Board Member 67 25/03/2015
Director/Board Member 66 25/03/2015
Director/Board Member 60 20/03/2018
Change 5-day change 1-year change 3-year change Capi.($)
+0.82%+1.10% - - 6.31B
+0.01%+4.40%+18.54%+104.90% 98.51B
-0.09%-3.09%+43.22%+145.22% 53.52B
-0.34%+3.90%+4.27%+266.25% 23.53B
-2.52%+2.98%-12.49%-21.65% 8.25B
-5.82%+2.45%-32.81%-32.05% 7.79B
-1.35%+5.02%-6.54%-27.10% 6.99B
+0.79%+2.77%-0.39%+25.12% 5.51B
-2.29%+2.00%-4.49%-6.59% 3.76B
+1.62%+8.06%+17.08%+21.47% 3.59B
Average -0.92%+3.10%+2.93%+52.84% 23.49B
Weighted average by Cap. -0.37%+2.52%+18.34%+113.24%

Financials

2026 *2027 *
Net sales 25.79B 3.95B 3.45B 3.18B 2.93B 5.53B 380B 5.65B 38.04B 14.96B 186B 14.82B 14.5B 641B 25.87B 3.96B 3.46B 3.19B 2.94B 5.55B 381B 5.67B 38.16B 15.01B 187B 14.87B 14.54B 643B
Net income 4.55B 697M 609M 562M 518M 976M 67.1B 998M 6.72B 2.64B 32.86B 2.62B 2.56B 113B 4.6B 704M 615M 567M 523M 986M 67.75B 1.01B 6.78B 2.67B 33.18B 2.64B 2.58B 114B
Net Debt 4.09B 626M 547M 505M 465M 877M 60.26B 896M 6.03B 2.37B 29.51B 2.35B 2.3B 102B -44.13M -6.75M -5.9M -5.45M -5.02M -9.46M -650M -9.67M -65.11M -25.61M -319M -25.37M -24.81M -1.1B
Logo Lundbeck
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,000
Date Price Change Volume
17/07/26 DKK 36.70 +0.82% 55,228
16/07/26 DKK 36.40 +0.83% 29,871
15/07/26 DKK 36.10 +0.70% 39,430
14/07/26 DKK 35.85 -1.38% 52,796
13/07/26 DKK 36.35 +0.14% 67,337
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
42.86DKK
Average target price
47.88DKK
Spread / Average Target
+11.70%

Quarterly revenue - Rate of surprise